MMP19 and chronic kidney disease: Based on the strong evidence of cardio‐renal protection offered by the addition of finerenone in the FIDELIO‐CKD and FIGARO‐CKD studies,43 we suggest in people with CKD who have persistent albuminuria (ACR >30 mg/mmol) despite the use of maximum tolerated doses of RASi and SGLT2i, to consider addition of finerenone to reduce the risk of adverse kidney and cardiovascular outcomes.